The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the effect of intravitreal bevacizumab injection (IVBI) in acute central serous chorioretinopathy (CSC) patients. Methods: Patients with acute CSC received IVBI (1.25 mg/0.05 mL) or observation by randomization. Twelve eyes in each group completed 6 months of regular follow-up and were ultimately included in this study. Each patient was assessed using best corrected visual acuity measurements, fluorescein angiography, and optical coherence tomography at baseline and had regular follow-ups after treatment. Results: All patients showed improvements in visual acuity and fluorescein angiographic leakage and had resolution of their neurosensory detachment following treatment. There were no significant differences in visual acuity, central retinal thickness, or remission duration between the IVBI group and the control group at baseline or after treatment (p＞0.05). Conclusions: Intravitreal bevacizumab showed no positive effect in acute CSC patients compared to the observation group, and there were no adverse effects of treatment. Further investigation will be helpful to understand this therapy in patients with CSC.
Abstract
Purpose: To evaluate the effect of intravitreal bevacizumab injection (IVBI) in acute central serous chorioretinopathy (CSC) patients. Methods: Patients with acute CSC received IVBI (1.25 mg/0.05 mL) or observation by randomization. Twelve eyes in each group completed 6 months of regular follow-up and were ultimately included in this study. Each patient was assessed using best corrected visual acuity measurements, fluorescein angiography, and optical coherence tomography at baseline and had regular follow-ups after treatment. Results: All patients showed improvements in visual acuity and fluorescein angiographic leakage and had resolution of their neurosensory detachment following treatment. There were no significant differences in visual acuity, central retinal thickness, or remission duration between the IVBI group and the control group at baseline or after treatment (p＞0.05). Conclusions: Intravitreal bevacizumab showed no positive effect in acute CSC patients compared to the observation group, and there were no adverse effects of treatment. Further investigation will be helpful to understand this therapy in patients with CSC.
참고문헌 (17)
- Gass JD, "Pathogenesis of disciform detachment of neuroepithelium: II. Idiopathic central serous choroidopathy", Am J Ophthalmol, 63, pp.587~615 (1967)
- Levine R, "Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography", Ophthalmology, 96, pp.854~859 (1989)
- Loo RH, "Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy", Retina, 22, pp.19~24 (2002)
- Chan WM, "Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial", Ophthalmology, 115, pp.1756~1765 (2008)
- Wang M, "Central serous chorioretinopathy", Acta Ophthalmol, 86, pp.126~145 (2008)
- Tolentino MJ, "Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate", Am J Ophthalmol, 133, pp.373~385 (2002)
- Torres-Soriano ME, "A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports)", Graefes Arch Clin Exp Ophthalmol, 246, pp.1235~1239 (2008)
- Eandi CM, "Acute central serous chorioretinopathy and fundus autofluorescence", Retina, 25, pp.989~993 (2005)
- Wong R, "Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy", Eye, 18, pp.262~268 (2004)
- Sharma T, "Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy", Ophthalmology, 111, pp.1708~1714 (2004)
- Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.363~372 (2006)
- Spaide RF, "Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration", Retina, 26, pp.383~390 (2006)
- Heiduschka P, "Penetration of bevacizumab through the retina after intravitreal injection in the monkey", Invest Ophthalmol Vis Sci, 48, pp.2814~2823 (2007)
- Shahar J, "Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)", Retina, 26, pp.262~269 (2006)
- Stanga PE, "Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update", Ophthalmology, 110, pp.15~21 (2003)
- Piccolino FC, "14:231-42", Retina, 14, pp.231~242 (1994)
- Seong HK, "Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect", Ophthalmologica, 223, pp.343~347 (2009)